How Cinfa Is Supporting the Future of Cardio-Metabolic Care in the Middle East

Cardiovascular disease and diabetes continue to represent two of the most significant health challenges across the Middle East. According to the 2025 IDF Diabetes Atlas, one in six adults across the Middle East and North Africa is living with diabetes, while cardiovascular disease remains one of the leading causes of mortality worldwide. These conditions rarely occur in isolation. High blood pressure, elevated cholesterol, excess weight, and type 2 diabetes frequently overlap, increasing both the complexity of treatment and the long-term burden on healthcare systems.

As healthcare systems across the region continue to prioritize prevention and long-term management of chronic disease, there is growing recognition that cardio-metabolic care requires more than individual therapies. It depends on providing physicians with access to treatment options that keep pace with patients’ evolving conditions over time, supported by consistent quality, reliable supply and continued scientific investment.

Against this backdrop, Cinfa has steadily expanded its presence across the Middle East over more than a decade, building a cardio-metabolic portfolio that has grown alongside the changing needs of patients and healthcare professionals.

Evolving Alongside Regional Healthcare Needs

Since entering the UAE in 2013, Cinfa has progressively expanded its presence across the Gulf, including Kuwait, Saudi Arabia, Qatar, and, in new addition, Bahrain and Iraq. Over that time, its cardio-metabolic offering has evolved from an initial focus on lipid management into a broader portfolio supporting hypertension and, more recently, type 2 diabetes.

This evolution reflects the realities of modern clinical practice. Patients living with cardio-metabolic conditions often require treatment intensification over time, and many are managing several interconnected conditions simultaneously. As a result, healthcare professionals increasingly require treatment options that support continuity of care across different stages of disease management rather than addressing conditions in isolation.

The portfolio expansion goes beyond individual product additions, reflecting a long-term commitment to supporting physicians as patient needs become increasingly complex across the region.

Building Confidence Through Quality and Long-Term Investment

In healthcare, the value of innovation is measured not only by the development of new therapies, but by their ability to deliver consistent, reliable care over the long term. For patients living with chronic conditions, quality, continuity and dependable supply are fundamental to successful treatment.

Cinfa’s work in the Middle East is supported by more than 57 years of experience in Spain, where the company holds a leading position in the pharmaceutical market, according to IQVIA data.  With two R&D centers and four manufacturing facilities, the company manages the full pathway from research and development through to production, helping maintain consistent quality while responding to evolving healthcare needs.

Continued investment in R&D&I and infrastructure underpins this approach, with $565 million invested in these areas in the past decade, supporting the expansion of treatment options while maintaining high manufacturing standards. 

Its medicines are developed and manufactured under the same European regulatory framework that governs quality and safety across EU markets. Each medicine also undergoes an average of 30 quality controls before reaching patients.

Together, these measures reflect the importance of consistency and reliability for medicines that many patients depend on throughout their lives.

Looking Ahead

As the prevalence of diabetes and cardiovascular disease continues to rise across the Middle East, strengthening cardio-metabolic care will remain a shared priority for healthcare systems, healthcare professionals, and industry alike.

For Cinfa, this means continuing to expand its cardio-metabolic offering in response to regional healthcare needs, with future developments across diabetes, anticoagulation, and the prevention of acute coronary syndrome subject to local regulatory approvals. More importantly, it means maintaining a long-term commitment to supporting healthcare professionals with treatment options that reflect the realities of managing chronic disease.

Ultimately, improving cardio-metabolic outcomes is not simply about increasing the number of available therapies. It is about ensuring that patients have reliable access to high-quality treatment throughout every stage of their healthcare journey. By combining sustained regional engagement with continued investment in research, manufacturing and quality, Cinfa aims to contribute to the long-term advancement of cardio-metabolic care across the Middle East.